SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Edén Engström Britt)
 

Sökning: WFRF:(Edén Engström Britt) > Limited value of ca...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00005573naa a2200517 4500
001oai:DiVA.org:oru-110281
003SwePub
008231215s2016 | |||||||||||000 ||eng|
009oai:lup.lub.lu.se:a4fbd21b-71b6-470b-9c5c-eefc99a67e32
009oai:DiVA.org:uu-272040
009oai:DiVA.org:liu-124115
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-1102812 URI
0247 a https://doi.org/10.1530/EJE-15-08072 DOI
0247 a https://lup.lub.lu.se/record/82351792 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-2720402 URI
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-1241152 URI
040 a (SwePub)orud (SwePub)lud (SwePub)uud (SwePub)liu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Burman, Piau Lund University,Lunds universitet,Genomik, diabetes och endokrinologi,Forskargrupper vid Lunds universitet,Genomics, Diabetes and Endocrinology,Lund University Research Groups,Lund Univ, Skane Univ Hosp Malmo, Dept Endocrinol, S-20502 Malmo, Sweden.,Department of Endocrinology, Skane University Hospital Malmö, University of Lund, Malmö, Sweden4 aut0 (Swepub:lu)med-bap
2451 0a Limited value of cabergoline in Cushing's disease :b a prospective study of a 6-week treatment in 20 patients
264 1b Bioscientifica,c 2016
338 a print2 rdacarrier
500 a Funding Agencies:Swedish Association of Local Authorities and RegionsLocal grants from University of Lund, Linköping and Uppsala
500 a Funding Agencies|Swedish Association of Local Authorities and Regions to the Swedish Pituitary Study Group; University of Lund; Linkoping; Uppsala
520 a CONTEXT AND OBJECTIVE: The role of cabergoline in Cushing's disease (CD) remains controversial. The experience is limited to case reports and few open studies that report the effects determined after ≥1 month of treatment. In prolactinomas and dopamine-responsive GH-secreting tumours, effects of cabergoline are seen within days or weeks. Here, we searched for short-term effects of cabergoline in CD.DESIGN: Twenty patients (19 naïve and one recurrent) were included in a prospective study. Cabergoline was administered in increasing doses of 0.5-5 mg/week over 6 weeks.METHODS: Urinary free cortisol (UFC) 24 h, morning cortisol and ACTH, and salivary cortisol at 0800, 1600 and 2300 h were determined once weekly throughout. Diurnal curves (six samples) of serum cortisol were measured at start and end.RESULTS: At study end, the median cabergoline dose was 5 mg, range 2.5-5 mg/week. The prolactin levels, markers of compliance, were suppressed in all patients. During the treatment, hypercortisolism varied, gradual and dose-dependent reductions were not seen. Five patients had a >50% decrease of UFC, three had a >50% rise of UFC. Salivary cortisol at 2300 h showed a congruent >50% change with UFC in two of the five cases with decreased UFC, and in one of the three cases with increased UFC. One patient with decreases in both UFC and 2300 h salivary cortisol also had a reduction in diurnal serum cortisol during the course of the study.CONCLUSIONS: Cabergoline seems to be of little value in the management of CD. Only one patient had a response-like pattern. Given the known variability of disease activity in CD, this might represent a chance finding.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicin0 (SwePub)3022 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicine0 (SwePub)3022 hsv//eng
7001 a Edén-Engström, Brittu Uppsala universitet,Endokrinologi och mineralmetabolism,Department of Diabetes, Endocrinology and Metabolism, University Hospital, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)brittee
7001 a Ekman, Bertilu Linköpings universitet,Medicinska fakulteten,Avdelningen för kardiovaskulär medicin,Region Östergötland, Endokrinmedicinska kliniken4 aut0 (Swepub:liu)berek83
7001 a Karlsson, Anders F.u Uppsala universitet,Klinisk diabetologi och metabolism,Department of Diabetes, Endocrinology and Metabolism, University Hospital, Uppsala University, Uppsala, Sweden4 aut0 (Swepub:uu)anderska
7001 a Schwarcz, Eriku Department of Internal Medicine, Faculty of Medicine and Health, Örebro University, Örebro, Sweden,Univ Orebro, Fac Med & Hlth, Dept Internal Med, SE-70182 Orebro, Sweden.4 aut
7001 a Wahlberg, Jeanette,d 1969-u Linköpings universitet,Medicinska fakulteten,Avdelningen för kardiovaskulär medicin,Region Östergötland, Endokrinmedicinska kliniken4 aut0 (Swepub:liu)jeawa98
7102 a Genomik, diabetes och endokrinologib Forskargrupper vid Lunds universitet4 org
7730 t European Journal of Endocrinologyd : Bioscientificag 174:1, s. 17-24q 174:1<17-24x 0804-4643x 1479-683X
8564 u http://www.ncbi.nlm.nih.gov/pubmed/26582653?dopt=Abstracty FULLTEXT
8564 u http://dx.doi.org/10.1530/EJE-15-0807y FULLTEXT
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-110281
8564 8u https://doi.org/10.1530/EJE-15-0807
8564 8u https://lup.lub.lu.se/record/8235179
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-272040
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-124115

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy